Literature DB >> 28456995

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

Rashmi Kanagal-Shamanna1, Juliana E Hidalgo Lopez1, Denái R Milton2, Hye Ryoun Kim1, Chong Zhao1, Zhuang Zuo1, Michelle Janania Martinez1, Francesco Stingo3, John Lee1, Rajyalakshmi Luthra1, Elias J Jabbour4, Guillermo Garcia-Manero4, L Jeffrey Medeiros1, Carlos E Bueso-Ramos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28456995      PMCID： PMC5872826          DOI： 10.1002/ajh.24776

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.

Authors:  Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2015-09       Impact factor: 10.047

2.  Validation of the WHO 2016 proposals for Myelodysplastic syndromes patients with the presence of ring sideroblasts but without excess blasts.

Authors:  Yi Li; Rui Cui; Tiejun Qin; Zefeng Xu; Yue Zhang; Wenyu Cai; Wen Cui; Jinqin Liu; Bing Li; Zhijian Xiao
Journal:  Br J Haematol       Date:  2016-06-13       Impact factor: 6.998

3.  New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.

Authors:  Corinna Strupp; Kathrin Nachtkamp; Barbara Hildebrandt; Aristoteles Giagounidis; Rainer Haas; Norbert Gattermann; John M Bennett; Carlo Aul; Ulrich Germing
Journal:  Leuk Res       Date:  2017-02-27       Impact factor: 3.156

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Authors:  Luca Malcovati; Elli Papaemmanuil; Ilaria Ambaglio; Chiara Elena; Anna Gallì; Matteo G Della Porta; Erica Travaglino; Daniela Pietra; Cristiana Pascutto; Marta Ubezio; Elisa Bono; Matteo C Da Vià; Angela Brisci; Francesca Bruno; Laura Cremonesi; Maurizio Ferrari; Emanuela Boveri; Rosangela Invernizzi; Peter J Campbell; Mario Cazzola
Journal:  Blood       Date:  2014-06-26       Impact factor: 22.113

6.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Authors:  E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245
  6 in total
  1 in total

1.  Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Authors:  Naoki Shingai; Yuka Harada; Hiroko Iizuka; Yosuke Ogata; Noriko Doki; Kazuteru Ohashi; Masao Hagihara; Norio Komatsu; Hironori Harada
Journal:  Int J Hematol       Date:  2018-10-23       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.